Status:
COMPLETED
Non-Interventional Study of Zoladex in Endometriosis
Lead Sponsor:
AstraZeneca
Conditions:
Endometriosis
Eligibility:
FEMALE
18+ years
Brief Summary
This is a prospective, open label NIS, which is to assess the efficacy of Zoladex in adjuvant setting after operation in moderate to severe endometriosis patients.
Eligibility Criteria
Inclusion
- Advanced endometriosis confirmed histologically (r-AFS score III-IV) with conservative laparoscopy or laparotomy.
- Patient who has the indication of Zoladex and has been prescribed Zoladex according to physician's judgement, irrespective of the inclusion in the study.
- Patient has been already prescribed Zoladex within 1 month after operation.
Exclusion
- Have used hormone treatment prior to 3 months of recruitment.
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
- Previous enrolment in the present study.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT00938496
Start Date
July 1 2009
End Date
February 1 2012
Last Update
February 20 2014
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Hefei, Anhui, China
2
Research Site
Beijing, Beijing Municipality, China
3
Research Site
Guangzhou, Guangdong, China
4
Research Site
Shenzhen, Guangdong, China